$TEM

Tempus AI, Inc.

Tempus is a healthcare technology company that applies artificial intelligence to diagnostics and connects laboratory results with patients’ clinical data to support treatment decisions. Its Tempus Platform links healthcare providers, diagnostic testing and life sciences customers through data connections and software. Tempus serves healthcare providers, pharmaceutical and biotechnology companies, researchers and other third parties. Tempus organizes its products into Diagnostics and Data and applications. Diagnostics includes oncology and hereditary testing, such as next-generation sequencing, PCR profiling, and anatomic and molecular pathology tests. Data and applications includes Insights, which licenses de-identified linked data and analytics tools; Trials, which supports clinical trial recruitment; and Next and Algos, AI-based products and algorithmic diagnostics. Hub provides a clinical interface for providers, while Lens supports research users. Tempus makes money by providing diagnostic testing and services and licensing de-identified data and analytical tools. It is headquartered in Chicago, Illinois.

AlphAI earnings readThird Quarter 2026 · NOV 2Tempus Reports Third Quarter 2026 ResultsVerdict: strong

Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.

0
2
3
—
$17.6M
LEFKOFSKY ERIC P
100%
See all $TEM insider activity →
Med

ARK Invest Adds $16.2 Million in NVIDIA and $16 Million in CoreWeave

ARK Invest added $16.2M to NVIDIA (NVDA) and $16M to CoreWeave (CRWV), while reducing positions in Tempus AI (TEM) and Palantir (PLTR) by $12.8M and $11.8M, respectively. Other buys included ACHR, TWST, PRME, and SOFI. Sells included AMZN, TER, SNPS, AVGO, XYZ, and BYDDY.

Tempus AI Earnings Call Highlights Growth and Scale

Tempus AI reported Q3 revenue of $412M, up 23% YoY. Diagnostics and oncology revenues grew 20% and 28%, respectively. The company highlighted major collaborations with BMS, Moderna, and Merck, and expects positive adjusted EBITDA. Management acknowledged reimbursement risks and Personalis' current losses but remains optimistic about growth opportunities, including a $20B MRD market.

Tempus CEO Eric Lefkofsky: A Blood Draw Can Catch Returning Cancer 6 to 12 Months Before a Scan

Tempus CEO Eric Lefkofsky reported a record quarter with 23% revenue growth, driven by 32% growth in cancer testing and 33% in data & AI applications. The company signed three $100M+ deals, including with Merck and Bristol Myers Squibb. Tempus claims its blood tests can detect cancer recurrence 6-12 months earlier than scans, leveraging its 600-petabyte data trove and 8,000 hospital integrations. The company is acquiring Personalis to expand into recurrence detection.

TEM sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 5 news stories mentioning TEM (Tempus AI, Inc.). Coverage has skewed bearish: 0 bullish, 2 neutral, and 3 bearish.

Recent TEM coverage spans financial news, earnings and market movers.

In the last 30 days, TEM insiders filed 26 SEC Form 4 transactions — no purchases and 26 sales ($17.6M). The most active reporter was LEFKOFSKY ERIC P, CEO and Chairman, with 24 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.

What's driving TEM

  • Tempus may face slight selling pressure.

    tokenpost.com · Nov 16, 2026

  • No new catalyst; price likely unchanged.

    tipranks.com · Nov 15, 2026

  • Tempus CEO Eric Lefkofsky reported a record quarter with 23% revenue growth, driven by 32% growth in cancer testing and 33% in data & AI applications. The company signed three $100M+ deals, including with Merck and Bristol Myers Squibb. Tempus claims its blood tests can detect cancer recurrence 6-12 months earlier than scans, leveraging its 600-petabyte data trove and 8,000 hospital integrations. The company is acquiring Personalis to expand into recurrence detection.

    finance.biggo.com · Nov 14, 2026

  • Negative signal for Tempus AI.

    stocktwits.com · Nov 13, 2026

  • Shares of NN, Fluence Energy, GRAIL, Tempus AI, and CSW fell due to leadership uncertainty at Nvidia, triggering broad declines in AI-related stocks. CSW's volatility and recent performance were highlighted, with its stock down 3.8% YTD and 19.2% below its 52-week high. JPMorgan previously upgraded CSW to 'Overweight' with a $350 price target.

    theglobeandmail.com · Nov 12, 2026

AlphAI scores every news story that mentions TEM with an AI model for sentiment and relevance, and aggregates insider trades from Tempus AI, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $TEM

Score

Tempus AI Earnings Call Highlights Growth and Scale

Tempus AI reported Q3 revenue of $412M, up 23% YoY. Diagnostics and oncology revenues grew 20% and 28%, respectively. The company highlighted major collaborations with BMS, Moderna, and Merck, and expects positive adjusted EBITDA. Management acknowledged reimbursement risks and Personalis' current losses but remains optimistic about growth opportunities, including a $20B MRD market.

Tempus CEO Eric Lefkofsky: A Blood Draw Can Catch Returning Cancer 6 to 12 Months Before a Scan

Tempus CEO Eric Lefkofsky reported a record quarter with 23% revenue growth, driven by 32% growth in cancer testing and 33% in data & AI applications. The company signed three $100M+ deals, including with Merck and Bristol Myers Squibb. Tempus claims its blood tests can detect cancer recurrence 6-12 months earlier than scans, leveraging its 600-petabyte data trove and 8,000 hospital integrations. The company is acquiring Personalis to expand into recurrence detection.

Cathie Wood Boosts Bets On 2 AI Firms Amid Nvidia’s Huang Upheaval — Here’s How Her Trading Week Unfolded

ARK Investment Management, led by Cathie Wood, disclosed $75.53M in stock purchases this week, including $16.16M in Nvidia (NVDA) and $16.02M in CoreWeave (CRWV). ARK also added to Archer Aviation (ACHR) and Rocket Lab (RKLB), while selling BYD (BYDDY) shares. CoreWeave reported $3.66B in revenue and a $132.5B backlog. Wood remains optimistic about AI and EV adoption.

$TEMLowContract· supplier

SOTERIA Collaborates with Tempus to Advance Precision Oncology for U.S. Military and Veterans Battling Cancer

SOTERIA Precision Medicine Foundation, a non-profit, partnered with Tempus (TEM) to provide personalized cancer treatment and genomic sequencing for U.S. military members and veterans. The collaboration supports SOTERIA's Cancer Hunt™ initiative, utilizing Tempus' AI-enabled diagnostic platform. Tempus is a publicly traded company on NASDAQ.

Related tickers